Arbutus Biopharma Corp 8-K

What Happened Arbutus Biopharma Corporation (ABUS) reported in an 8-K filed May 27, 2026 that at its May 26, 2026 Annual General and Special Meeting shareholders approved the Company’s 2026 Omnibus Share and Incentive Plan. The new plan, previously approved by the Board on April 10, 2026, authorizes issuance of 16,300,000 common shares and replaces the Company’s 2011 and 2016 omnibus plans. Shareholders also re-elected all five director nominees and approved Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal 2026.

Key Details

• 2026 Plan: Authorized up to 16,300,000 common shares; Board-approved April 10, 2026; full plan filed as Exhibit 10.1 to the 8-K.
• Plan vote: For 138,877,189; Against 7,408,185; Abstained 188,253; Broker non‑votes 22,829,831.
• Director elections (each elected to serve until 2027):
  • Lindsay Androski: For 136,780,089; Withheld 9,693,538
  • Robert Alan Beardsley: For 138,456,756; Withheld 8,016,871
  • Joseph Bishop: For 137,372,240; Withheld 9,101,387
  • Matthew Gline: For 126,670,273; Withheld 19,803,354
  • Roger Sawhney, MD: For 139,299,405; Withheld 7,174,222
• Executive compensation (advisory) vote: For 137,629,207; Against 8,331,760; Abstained 512,660.
• Auditor appointment vote (Ernst & Young LLP): For 164,372,596; Against 2,123,916; Abstained 2,806,946.

Why It Matters Approval of the 2026 Omnibus Plan gives the company a refreshed equity award pool (16.3M shares) to grant stock options, restricted shares or other awards to employees and directors — a tool for compensation and retention but one that can increase share count and potential dilution. Re-election of all five directors signals board continuity. Appointment of Ernst & Young as auditor confirms the firm that will audit fiscal 2026 financial statements. Investors should note the plan size and vote outcomes when assessing potential dilution and governance continuity.